Product Information
OXYBUTYNIN CL ER 5 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.0841 per EA under NDC 68382025501. Its NADAC has been published 439 times since May 9, 2018.
FDA first approved this application on Jun 26, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382025501
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202332FDA Approved
6/26/2017
TE Code
AB
On Market Since
8/10/2017
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN CL ER 5 MG TABLET has been published 439 times since May 9, 2018, and over the history we have for it it has declined 80.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0841 per EA |
|---|---|
| All-time high | $0.4449 (Jul 11, 2018) |
| All-time low | $0.0765 (Nov 20, 2024) |
| 52-week high | $0.0990 |
| 52-week low | $0.0817 |
| Median price | $0.1268 |
| Average price | $0.1837 |
| Largest weekly change | +35.7% (Jun 19, 2024) |
| Weeks tracked | 439 |
| Tracking since | May 9, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
oxybutynin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN CL ER 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN CL ER 5 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.0841 per EA (NDC 68382025501), effective Sep 30, 2026.
How has the price of OXYBUTYNIN CL ER 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has declined 80.6%. It has been tracked across 439 weekly CMS publications since May 9, 2018.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN CL ER 5 MG TABLET?
Since May 9, 2018, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has ranged from a low of $0.0765 (Nov 20, 2024) to a high of $0.4449 (Jul 11, 2018), with a median of $0.1268 per EA.
Are there cheaper alternatives to OXYBUTYNIN CL ER 5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as OXYBUTYNIN CL ER 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures OXYBUTYNIN CL ER 5 MG TABLET?
OXYBUTYNIN CL ER 5 MG TABLET (NDC 68382025501) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.